In a multi-stakeholder industry such as that of Orphan Drugs, communication is vital to ensuring strong, effective working relationships. Charles Stark from Emmaus Lifesciences joined …
Keynote announced – FDA Commissioner Dr. Robert Califf to tackle precision medicine focus
NEW YORK – Dr. Robert Califf, the recently appointed Commissioner of the U.S. Food and Drug Administration (FDA), will be presenting the opening address on …
#WODC USA Session preview- Pricing & Reimbursement workshop
#WODC USA Session preview- Pricing & Reimbursement workshop Medical Marketing Economics (MME) has completed 125+ orphan price strategies in the last three years. We will …
#WODC USA Session preview: Achieving Commercial Success for Orphan Drugs
#WODC USA Session preview: Achieving Commercial Success for Orphan Drugs Commercializing and launching orphan drugs is a vastly different challenge with different needs and requiring …
Social Finance and Social Impact Bonds for financing rare disease research: The CWR-UK experience
“Social Finance can create new economic engines for the repurposing of generic drugs, especially for rare diseases. There are needed repurposing opportunities that can yield low …
Positive Collaboration – Alström Syndrome UK
Kerry Leeson-Beevers, National Development Manager at Alström Syndrome UK joined us at World Orphan Drug Congress Europe 2015 to provide insight into the role how positive collaboration …
Calling all orphan drug biotech – Pitch & Partner!
View PostAnnouncing the 2016 World Orphan Drug Congress USA brochure
We are thrilled to announce the release of the 2016 World Orphan Drug Congress USA brochure! Following 5 years of success, the 6th Annual World Orphan …